Sofinnova Partners Congratulates Portfolio Company DNA Script for the Success of Its €142M ($165M) Oversubscribed Series C Fundraise
26.10.2021 16:00:00 EEST | Business Wire | Press release
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its portfolio company DNA Script has raised €142 million ($165 million) in a Series C financing led by top global investors, bringing the total amount raised to date by the company to €236 million ($280 million). DNA Script is a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand. The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.
DNA Script is a leader in enzymatic DNA synthesis and has developed a revolutionary platform that provides in-house DNA printing using a sustainable process that eliminates the use of toxic organic chemicals. The company’s ground-breaking approach to DNA printing significantly shortens wait times by enabling labs of all sizes to take full control of their DNA printing needs from the comfort of their own facilities – like having a home printer. No longer having to rely on third-party providers, researchers gain unprecedented control and autonomy, ultimately helping to accelerate innovation.
Joško Bobanović, Partner at Sofinnova Partners, said: “As the first institutional investor in DNA Script, it is incredibly gratifying to have been part of the growth and evolution of the company from the start. This milestone confirms our early conviction in the strength of the team and the magnitude of their vision to revolutionize a well-established chemical technology by applying biotechnology. The overwhelming interest from the global community further affirms our long-standing belief in the uniqueness and potential of the company’s technology to fundamentally change how DNA is synthesized by mimicking nature, while remaining entirely sustainable.”
Thomas Ybert, co-founder and CEO of DNA Script, said: “Sofinnova Partners was our first institutional investor and a strong believer in our vision from the beginning. Their hands-on role throughout critical early-stage financing rounds, and as an active member of our Board of Directors, has been instrumental in enabling us to rapidly scale to become a global operation and attract top notch investors from all over the world.”
The Sofinnova Industrial Biotech strategy is part of Sofinnova’s multi-fund investment platform that covers the entire life sciences value chain. It is a highly-targeted strategy that seeks to invest in start-ups that are addressing global sustainability issues in food, agricultural, chemicals and materials markets.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005360/en/
Contact information
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Rafaella Casula
rafaella.casula@havaspr.com
+39 (0) 345 3780834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Industry Study Finds Quantum Computing Has Entered a Capability Era, With Early Movers Building an Advantage Later Entrants Will Struggle to Close18.6.2026 10:00:00 EEST | Press release
Quantum computing has moved past the question of whether organizations can access a quantum system and onto whether they can build something useful around one. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618639340/en/ State of Quantum 2026 is based on independently conducted research and analysis, authored by The Quantum Insider (Resonance), published by IQM Quantum Computers, and supported by OpenOcean. According to the State of Quantum 2026, the fourth annual industry study published today by IQM Quantum Computers, which is nearing its planned listing on the Nasdaq Global Select Market through its merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ), with research and analysis independently conducted by The Quantum Insider, a Resonance company — enterprise engagement is now nearly universal but production use remains rare: 89% of respondents report hands-on quantum work, while only 10% report limited production us
Climate Clock Public Art Trail Opens Across Oulu18.6.2026 09:45:00 EEST | Press release
The permanent Climate Clock art trail brings together seven internationally recognised artists in site-specific works across forests, rivers, coastlines, urban environments and cultural heritage sites. The works reflect on climate change and different perceptions of time through sculpture, ceramics, natural materials, sound and kinetic forms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617018262/en/ Antti Laitinen – You Are Here (2026), Maija Laitinen/Oulu2026 Already attracting international attention, Climate Clock offers a new public art experience connecting art, science and the northern landscape across the region. The trail opened to the public on 13 June 2026 across six locations: Yli-Ii, Oulu city centre, Ylikiiminki, Oulunsalo, Kiiminki and Kello. Opening events brought together artists, local communities and visitors, activating the works across the region. Curated by Alice Sharp (Invisible Dust, UK) and prod
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 05:00:00 EEST | Press release
JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products and adapt flexibly to changing customer needs. EXO Travel's unique
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 02:01:00 EEST | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together, the companies will aim to develop a novel, tumour-selective therapeutic targeting a solid tumour antigen expressed across multiple difficult-to-treat cancer types. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615992992/en/ “Partnering with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to design highly optimised multispecific antibodies,”said Dr. James Field, CEO of LabGenius. “We welcome this opp
Joe Vernachio Named President of SOREL18.6.2026 01:00:00 EEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom